A recent study showed that cell lines harboring TGFBR2 mutants failed to respond to exogenous TGF‐β stimulation, and re‐expression of wild‐type TGFBR2 restored canonical TGF‐β signaling and proliferative inhibition, confirming the mutational loss of TGF‐β tumor suppressive activity.64 Therefore, germline TGFBR2 mutations could be one of the causes of familiar CRC without MMR dysfunction. The gene discussed is TGFBR2; the disease is colorectal carcinoma.